Macular Degeneration

Home/Disease Specific/Macular Degeneration

Stem cell scientists take hope from first human trials but see long road ahead

Monday, June 4, 2012 By: Sarah Boseley Much hangs on outcome of first human trials amid funding difficulties, political opposition and public suspicion Health Editor, guardian.co.uk Marcus Hilton sits in front of the TV and stares at the Sky News headlines scrolling along the bottom of the screen. If he moves his head about he

Blindness Study Opens the Door for Further Stem Cell Trials

Wednesday, February 15, 2012 By: Jason Koebler Success, without side effects, will allow human research to continue January 25, 2012 US News & World Report Monday, news broke that researchers improved the vision of two legally blind women by injecting embryonic stem cells into their eyes. Some media outlets are hailing the findings as showing a

Stem-cell breakthrough improves vision in blind patients

Wednesday, February 15, 2012 By: Bradley Bouzane A glimpse of hope was offered to blind people this week afgter US clinical trials showed transplanted stem cells improved the sight of two patients with severe vision problems. The research, which is touted as the first use of embryonic stem cells being transplanted into a human patient,

Leading Eye Institute to Participate in ACT’s Embryonic Stem Cell Clinical Trial for Macular Degeneration

Tuesday, January 17, 2012 By: Business Wire Wills Eye Institute receives IRB approval to treat dry-AMD using ACT's hESC-derived retinal pigment epithelial (RPE) cells. Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site

Stem Cells in Eyes Offer Hope for Reversing Leading Cause of Blindness in Seniors

Thursday, January 5, 2012 By: Sheryl Ubelacker, The Canadian Press Eyes have been called the window to the soul, but they are also proving to be a potential wellspring for regenerative medicine. Researchers say they have discovered a new source of stem cells at the back of the eye, which they hope may one day

Firm Launches Two Stem Cell Trials Against Blindness

Thursday, July 14, 2011 By: Meredith Wadman, Nature Tests begin on patients with Stargardt's Macular Dystrophy and Age-related Macular Degeneration. Geron made medical history last October, when it treated subject number one in the first-ever trial of a human embryonic stem cell (hESC) therapy, for spinal cord injury. Now, the second and third hESC trials have been

Stem Cell Clinical Trials to Treat Eye Diseases Begin at UCLA

Thursday, July 14, 2011 By: Daniela Hernandez, Los Angeles Times After more than 20 years of research, doctors at UCLA's Jules Stein Eye Institute have begun treating the first patients in clinical trials for two progressive eye diseases that cause blindness: dry age-related macular degeration and Stargardt's macular dystrophy. The patients were given an injection

ACT: First Patients Enrolled in Two Clinical Trials Using Embryonic Stem Cells to Treat Stargardt’s and Macular Degeneration

Thursday, June 16, 2011 By: Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the enrollment of the first patients in its two Phase 1/2 clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived

Researchers Report Progress Using iPS Cells to Reverse Blindness

Wednesday, June 15, 2011 By: Indiana University-Purdue University Indianapolis Researchers have used cutting-edge stem cell technology to correct a genetic defect present in a rare blinding disorder, another step on a promising path that may one day lead to therapies to reverse blindness caused by common retinal diseases such as macular degeneration and retinitis pigmentosa

ACT Names Test Sites for Stargardt’s Macular Dystrophy Therapy

Monday, May 16, 2011 By: Advanced Cell Technology Inc. Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the Casey Eye Institute (CEI) at Oregon Health & Science University (OHSU) in Portland, Ore., has received institutional review board (IRB) approval to be a site for its Phase 1/2 human